Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

269 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications.
McMillin DW, Delmore J, Negri J, Buon L, Jacobs HM, Laubach J, Jakubikova J, Ooi M, Hayden P, Schlossman R, Munshi NC, Lengauer C, Richardson PG, Anderson KC, Mitsiades CS. McMillin DW, et al. Among authors: hayden p. Br J Haematol. 2011 Feb;152(4):420-32. doi: 10.1111/j.1365-2141.2010.08427.x. Epub 2011 Jan 11. Br J Haematol. 2011. PMID: 21223249 Free PMC article.
Novel therapies in myeloma.
Hayden PJ, Mitsiades CS, Anderson KC, Richardson PG. Hayden PJ, et al. Curr Opin Hematol. 2007 Nov;14(6):609-15. doi: 10.1097/MOH.0b013e3282f0e948. Curr Opin Hematol. 2007. PMID: 17898564 Review.
Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
McMillin DW, Ooi M, Delmore J, Negri J, Hayden P, Mitsiades N, Jakubikova J, Maira SM, Garcia-Echeverria C, Schlossman R, Munshi NC, Richardson PG, Anderson KC, Mitsiades CS. McMillin DW, et al. Among authors: hayden p. Cancer Res. 2009 Jul 15;69(14):5835-42. doi: 10.1158/0008-5472.CAN-08-4285. Epub 2009 Jul 7. Cancer Res. 2009. PMID: 19584292
In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465.
Negri JM, McMillin DW, Delmore J, Mitsiades N, Hayden P, Klippel S, Hideshima T, Chauhan D, Munshi NC, Buser CA, Pollard J, Richardson PG, Anderson KC, Mitsiades CS. Negri JM, et al. Among authors: hayden p. Br J Haematol. 2009 Dec;147(5):672-6. doi: 10.1111/j.1365-2141.2009.07891.x. Epub 2009 Sep 14. Br J Haematol. 2009. PMID: 19751238 Free PMC article.
Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib.
Ooi MG, Hayden PJ, Kotoula V, McMillin DW, Charalambous E, Daskalaki E, Raje NS, Munshi NC, Chauhan D, Hideshima T, Buon L, Clynes M, O'Gorman P, Richardson PG, Mitsiades CS, Anderson KC, Mitsiades N. Ooi MG, et al. Among authors: hayden pj. Clin Cancer Res. 2009 Dec 1;15(23):7153-60. doi: 10.1158/1078-0432.CCR-09-1071. Epub 2009 Nov 24. Clin Cancer Res. 2009. PMID: 19934289 Free PMC article.
Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma.
Weisel K, Dimopoulos M, Moreau P, Yagci M, Larocca A, Kanate AS, Vural F, Cascavilla N, Basu S, Johnson P, Byeff P, Hus M, Rodríguez-Otero P, Muelduer E, Anttila P, Hayden PJ, Krauth MT, Lucio P, Ben-Yehuda D, Mendeleeva L, Guo S, Yu X, Grote L, Biyukov T, Dhanasiri S, Richardson P. Weisel K, et al. Among authors: hayden pj. Leuk Lymphoma. 2020 Aug;61(8):1850-1859. doi: 10.1080/10428194.2020.1747066. Epub 2020 Apr 9. Leuk Lymphoma. 2020. PMID: 32268815
269 results